ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 569,32
-0,83%
Dow Jones
40 211,72
0,00%
DAX
18 483,86
-0,63%
Brent Oil
82,94
-1,66%
Bitcoin
63 744,93
-1,71%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
03/10/201809h00GlobeNewswire Inc.Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018NASDAQ:SMMTSummit Therapeutics Inc
26/09/201809h00GlobeNewswire Inc.Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disea...NASDAQ:SMMTSummit Therapeutics Inc
20/09/201815h36Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
20/09/201809h00GlobeNewswire Inc.Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
14/09/201809h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018NASDAQ:SMMTSummit Therapeutics Inc
14/09/201809h00GlobeNewswire Inc.Summit Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
06/09/201809h00GlobeNewswire Inc.Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen TargetsNASDAQ:SMMTSummit Therapeutics Inc
05/09/201809h00GlobeNewswire Inc.Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of GonorrhoeaNASDAQ:SMMTSummit Therapeutics Inc
03/09/201811h12GlobeNewswire Inc.Total voting rightsNASDAQ:SMMTSummit Therapeutics Inc
29/08/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment ConferenceNASDAQ:SMMTSummit Therapeutics Inc
16/08/201813h00GlobeNewswire Inc.Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. diff...NASDAQ:SMMTSummit Therapeutics Inc
06/08/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
02/08/201820h00GlobeNewswire Inc.Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile In...NASDAQ:SMMTSummit Therapeutics Inc
30/07/201816h47PR Newswire (US)Summit Therapeutics Joins Antimicrobials Working GroupNASDAQ:SMMTSummit Therapeutics Inc
28/06/201823h06Dow Jones NewsADRs End HigherNASDAQ:SMMTSummit Therapeutics Inc
27/06/201813h00GlobeNewswire Inc.Summit Announces PhaseOut DMD Did Not Meet Primary EndpointNASDAQ:SMMTSummit Therapeutics Inc
15/06/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
11/06/201813h00GlobeNewswire Inc.Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018NASDAQ:SMMTSummit Therapeutics Inc
05/06/201813h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
01/06/201813h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018NASDAQ:SMMTSummit Therapeutics Inc
30/05/201812h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
15/05/201822h49Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:SMMTSummit Therapeutics Inc
09/05/201819h59Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
23/04/201813h00GlobeNewswire Inc.Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Present...NASDAQ:SMMTSummit Therapeutics Inc
23/04/201812h45GlobeNewswire Inc.Award of Share Options and Restricted Stock UnitsNASDAQ:SMMTSummit Therapeutics Inc
20/04/201813h00GlobeNewswire Inc.Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual MeetingNASDAQ:SMMTSummit Therapeutics Inc
19/04/201813h00GlobeNewswire Inc.Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialNASDAQ:SMMTSummit Therapeutics Inc
13/04/201815h08Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
11/04/201813h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Pr...NASDAQ:SMMTSummit Therapeutics Inc
09/04/201816h01GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

BIT
UC41JB
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés